Skip to main content

Phenazopyridine Hydrochloride Shortage

Last Updated: August 6, 2016
Status: Resolved

Products Affected - Description
    • Pyridium oral tablet, Gemini Laboratories, 100 mg, 100 count, NDC 60846-0517-01
    • Pyridium oral tablet, Gemini Laboratories, 200 mg, 100 count, NDC 60846-0520-01
    • Phenazopyridine oral tablet, Avkare, 100 mg, 90 count, NDC 42291-0670-90
    • Phenazopyridine oral tablet, Avkare, 200 mg, 90 count, NDC 42291-0671-90
    • Phenazopyridine oral tablet, Marlex, 100 mg, 6 count, NDC 10135-0199-78
    • Phenazopyridine oral tablet, Marlex, 100 mg, 30 count, NDC 10135-0199-30
    • Phenazopyridine oral tablet, Marlex, 100 mg, 1000 count, NDC 10135-0199-10
Reason for the Shortage
    • Amneal Pharmaceuticals, Avkare, SDA Laboratories discontinued phenazopyridine tablets.
    • Gemini Laboratories has new NDC numbers for Pyridium products. Gemini has product available.
    • Marlex has new NDC numbers for the generic phenazopyridine 100 mg and 200 mg tablets. These are available.
Available Products
    • Pyridium oral tablet, Gemini Laboratories, 100 mg, 100 count, NDC 60846-0501-01
    • Pyridium oral tablet, Gemini Laboratories, 200 mg, 100 count, NDC 60846-0502-01
    • Phenazopyridine oral tablet, Marlex, 100 mg, 100 count, NDC 10135-0620-01
    • Phenazopyridine oral tablet, Marlex, 200 mg, 100 count, NDC 10135-0621-01

Estimated Resupply Dates

    • Marlex has phenazopyridine 100 mg and 200 mg tablets available.
    • Gemini Laboratories has Pyridium 100 mg and 200 mg tablets available.

Updated

Updated August 6, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 20, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer